Ecografia con mezzo di contrasto nel follow-up di pazienti con metastasi epatiche da carcinoma mammario

Translated title of the contribution: Contrast-enhanced ultrasonography in the follow-up of patients with hepatic metastases from breast carcinoma

P. Della Vigna, F. Cernigliaro, L. Monfardini, S. Gandini, M. Bellomi

Research output: Contribution to journalArticle

Abstract

Purpose. Oncological treatment planning relies on the evaluation of treatment response, which is defined by the change in size of measurable lesions. The purpose of this study was to evaluate the use of contrast-enhanced ultrasound (CEUS) to obtain a precise measurement of hepatic metastases in breast cancer patients with fatty-liver disease. Materials and methods. Twelve consecutive patients with 25 liver metastases from breast cancer and fatty liver disease, as defined by US criteria, were enrolled in this prospective study. All patients underwent conventional US, CEUS and multidetector computed tomography (MDCT), used as the gold standard for measuring the maximum diameter of lesions. Agreement between US, CEUS and MDCT measurements was analysed using Altman-Bland plots; 95% confidence limits were calculated for the difference among means. Results. Mean diameter as measured by MDCT was 26.2 mm (range 11-83). US allowed measurement of 20/25 lesions. In 15 lesions, CEUS measurements were more accurate than those obtained by US. The difference among means was 1.1 mm with a 95% confidence interval (-9.2, 11.4) for US measurements and 0.6 mm with a 95% confidence interval (-2.0, 3.1) for CEUS. Conclusions. Our preliminary data show that CEUS can be used to obtain more accurate measurements than conventional US for the follow-up of patients with metastases in fatty liver.

Original languageItalian
Pages (from-to)47-55
Number of pages9
JournalRadiologia Medica
Volume112
Issue number1
DOIs
Publication statusPublished - Feb 2007

Fingerprint

Multidetector Computed Tomography
Ultrasonography
Fatty Liver
Breast Neoplasms
Neoplasm Metastasis
Liver
Liver Diseases
Confidence Intervals
Liver Neoplasms
Prospective Studies
Therapeutics

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Ecografia con mezzo di contrasto nel follow-up di pazienti con metastasi epatiche da carcinoma mammario. / Della Vigna, P.; Cernigliaro, F.; Monfardini, L.; Gandini, S.; Bellomi, M.

In: Radiologia Medica, Vol. 112, No. 1, 02.2007, p. 47-55.

Research output: Contribution to journalArticle

@article{4f5f15f843334d2f81b36212889937dd,
title = "Ecografia con mezzo di contrasto nel follow-up di pazienti con metastasi epatiche da carcinoma mammario",
abstract = "Purpose. Oncological treatment planning relies on the evaluation of treatment response, which is defined by the change in size of measurable lesions. The purpose of this study was to evaluate the use of contrast-enhanced ultrasound (CEUS) to obtain a precise measurement of hepatic metastases in breast cancer patients with fatty-liver disease. Materials and methods. Twelve consecutive patients with 25 liver metastases from breast cancer and fatty liver disease, as defined by US criteria, were enrolled in this prospective study. All patients underwent conventional US, CEUS and multidetector computed tomography (MDCT), used as the gold standard for measuring the maximum diameter of lesions. Agreement between US, CEUS and MDCT measurements was analysed using Altman-Bland plots; 95{\%} confidence limits were calculated for the difference among means. Results. Mean diameter as measured by MDCT was 26.2 mm (range 11-83). US allowed measurement of 20/25 lesions. In 15 lesions, CEUS measurements were more accurate than those obtained by US. The difference among means was 1.1 mm with a 95{\%} confidence interval (-9.2, 11.4) for US measurements and 0.6 mm with a 95{\%} confidence interval (-2.0, 3.1) for CEUS. Conclusions. Our preliminary data show that CEUS can be used to obtain more accurate measurements than conventional US for the follow-up of patients with metastases in fatty liver.",
keywords = "Breast cancer, Contrast-enhanced ultrasound, Liver metastasis, Ultrasound contrast agent",
author = "{Della Vigna}, P. and F. Cernigliaro and L. Monfardini and S. Gandini and M. Bellomi",
year = "2007",
month = "2",
doi = "10.1007/s11547-007-0119-7",
language = "Italian",
volume = "112",
pages = "47--55",
journal = "Radiologia Medica",
issn = "0033-8362",
publisher = "Springer-Verlag Italia s.r.l.",
number = "1",

}

TY - JOUR

T1 - Ecografia con mezzo di contrasto nel follow-up di pazienti con metastasi epatiche da carcinoma mammario

AU - Della Vigna, P.

AU - Cernigliaro, F.

AU - Monfardini, L.

AU - Gandini, S.

AU - Bellomi, M.

PY - 2007/2

Y1 - 2007/2

N2 - Purpose. Oncological treatment planning relies on the evaluation of treatment response, which is defined by the change in size of measurable lesions. The purpose of this study was to evaluate the use of contrast-enhanced ultrasound (CEUS) to obtain a precise measurement of hepatic metastases in breast cancer patients with fatty-liver disease. Materials and methods. Twelve consecutive patients with 25 liver metastases from breast cancer and fatty liver disease, as defined by US criteria, were enrolled in this prospective study. All patients underwent conventional US, CEUS and multidetector computed tomography (MDCT), used as the gold standard for measuring the maximum diameter of lesions. Agreement between US, CEUS and MDCT measurements was analysed using Altman-Bland plots; 95% confidence limits were calculated for the difference among means. Results. Mean diameter as measured by MDCT was 26.2 mm (range 11-83). US allowed measurement of 20/25 lesions. In 15 lesions, CEUS measurements were more accurate than those obtained by US. The difference among means was 1.1 mm with a 95% confidence interval (-9.2, 11.4) for US measurements and 0.6 mm with a 95% confidence interval (-2.0, 3.1) for CEUS. Conclusions. Our preliminary data show that CEUS can be used to obtain more accurate measurements than conventional US for the follow-up of patients with metastases in fatty liver.

AB - Purpose. Oncological treatment planning relies on the evaluation of treatment response, which is defined by the change in size of measurable lesions. The purpose of this study was to evaluate the use of contrast-enhanced ultrasound (CEUS) to obtain a precise measurement of hepatic metastases in breast cancer patients with fatty-liver disease. Materials and methods. Twelve consecutive patients with 25 liver metastases from breast cancer and fatty liver disease, as defined by US criteria, were enrolled in this prospective study. All patients underwent conventional US, CEUS and multidetector computed tomography (MDCT), used as the gold standard for measuring the maximum diameter of lesions. Agreement between US, CEUS and MDCT measurements was analysed using Altman-Bland plots; 95% confidence limits were calculated for the difference among means. Results. Mean diameter as measured by MDCT was 26.2 mm (range 11-83). US allowed measurement of 20/25 lesions. In 15 lesions, CEUS measurements were more accurate than those obtained by US. The difference among means was 1.1 mm with a 95% confidence interval (-9.2, 11.4) for US measurements and 0.6 mm with a 95% confidence interval (-2.0, 3.1) for CEUS. Conclusions. Our preliminary data show that CEUS can be used to obtain more accurate measurements than conventional US for the follow-up of patients with metastases in fatty liver.

KW - Breast cancer

KW - Contrast-enhanced ultrasound

KW - Liver metastasis

KW - Ultrasound contrast agent

UR - http://www.scopus.com/inward/record.url?scp=33847682237&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33847682237&partnerID=8YFLogxK

U2 - 10.1007/s11547-007-0119-7

DO - 10.1007/s11547-007-0119-7

M3 - Articolo

C2 - 17310292

AN - SCOPUS:33847682237

VL - 112

SP - 47

EP - 55

JO - Radiologia Medica

JF - Radiologia Medica

SN - 0033-8362

IS - 1

ER -